Related Experiment Video
Updated: Dec 28, 2025
12:10
Retzius-Sparing Robot-Assisted Radical Prostatectomy
Published on: May 19, 2022
8.8K
Self-Reported Burden in Elderly Patients With Localized Prostate Cancer Treated With Stereotactic Body Radiation
Nima Aghdam1, Abigail Pepin1,2, Michael Carrasquilla1
1Department of Radiation Medicine, Georgetown University Hospital, Washington, DC, United States.
Frontiers in Oncology
|February 11, 2020
Summary
Most elderly prostate cancer patients treated with SBRT report low burden, with self-reported issues aligning with side effects measured by the Expanded Prostate Cancer Index Composite (EPIC)-26 questionnaire.
Area of Science:
- Oncology
- Geriatric Medicine
- Quality of Life Research
Background:
- Maintaining quality of life is crucial for elderly patients undergoing prostate cancer treatment.
- Stereotactic Body Radiation Therapy (SBRT) is a treatment option for prostate cancer.
- Validated questionnaires like EORTC QLQ-ELD14 and EPIC-26 assess patient-reported outcomes.
Purpose of the Study:
- To evaluate self-reported burden in elderly prostate cancer patients treated with SBRT.
- To examine the correlation between self-reported burden and treatment side effects.
- To assess the utility of the EORTC QLQ-ELD14 and EPIC-26 questionnaires in this population.
Main Methods:
- Cross-sectional cohort study of patients aged ≥70 with localized prostate cancer treated with SBRT ± Androgen Deprivation Therapy (ADT).
- Utilized EORTC QLQ-ELD14 for burden assessment and EPIC-26 for symptom measurement.
- Correlated ELD-14 burden domains with EPIC-26 scores using Spearman correlation.
Main Results:
- A minority of patients reported high burden from prostate cancer or SBRT treatment.
- Patient-reported treatment burden correlated well with EPIC-26 domains.
- Patients receiving ADT reported higher burden compared to non-ADT patients.
Conclusions:
- SBRT for localized prostate cancer appears to impose a low burden on most elderly patients.
- Self-reported burden aligns with objective measures of treatment side effects (EPIC-26).
- ADT is associated with increased patient burden in this cohort.
